*nih.life
			Clinical Trial Sponsors: Hospital Authority, Hong Kong

  Source:		NCT00578825


    		A Multi-centre, Double-blinded, Randomized,
     		Placebo-controlled Trial on the Efficacy and
			Safety of Lopinavir / Ritonavir Plus Ribavirin in
			the Treatment of Severe Acute Respiratory Syndrome

			Unknown status

			First Update December 20, 2007
			Last Update August 21, 2013

			Brief Summary
			The study aims to examine whether the
			combination of Lopinavir/Ritonavir plus Ribavirin
			for treatment of severe acute respiratory syndrome
			(SARS) is superior to placebo.

     		                         Embed       Tweet       Print